Clinical Trials Browser

Interventional × Epstein-Barr Virus Infections × 90 days × Clear all

NCT03258567 2026-04-08

Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas

Phase 2 Recruiting

Lymphoma, Lymphoproliferative Disorders, Epstein-Barr Virus Infections

NCT02135042 2026-04-03

Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA

Phase 2/3 Active not recruiting

Nasopharyngeal Carcinoma, Epstein-Barr Virus Infections

NCT06119256 2026-04-02

Clinical Study of EBV-TCR-T Cells for EBV Infection After Allogenic HSCT

Phase 1 Recruiting

Epstein-Barr Virus Infections

NCT06908096 2026-03-30

Epstein-Barr Virus (EBV) gH/gL/gp42-Ferritin Nanoparticle Vaccine With or Without gp350-Ferritin in Healthy Adults With or Without EBV Infection

Phase 1 Recruiting

Infectious Mononucleosis, Epstein-Barr Virus Infections

NCT07478952 2026-03-24

A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189 in Healthy Adults 18 to 30 Years of Age

Phase 1 Recruiting

Epstein-Barr Virus Infections

NCT06256484 2026-03-11

A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Phase 1 Terminated

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Epstein-Barr Virus Infections, Lymphoma, Mantle-Cell

NCT03394365 2026-02-20

ALLELE

Phase 3 Recruiting

Lymphoproliferative Disorders, Epstein-Barr Virus Infections

NCT04554914 2026-02-20

A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases

Phase 2 Recruiting

LymphoidSarcoma

Immunologic Deficiency Syndromes, Leiomyosarcoma, Lymphoproliferative Disorders, Epstein-Barr Virus Infections

NCT05389423 2026-02-19

Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas

Phase 1 Recruiting

Plasmablastic Lymphoma, Burkitt Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Epstein-Barr Virus Infections

NCT06761677 2026-02-05

A Phase 1b/2 Study of Intravenous Brincidofovir in Patients With Relapsed or Refractory Lymphoma and Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma

Phase 1/2 Suspended

LymphoidOther hematologic neoplasm

Immunoblastic Lymphadenopathy, Lymphoma, Recurrence, Leukemia-Lymphoma, Adult T-Cell, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic, Epstein-Barr Virus Infections, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT07368634 2026-01-28

Exploratory Study of EBV-TCR-T Cell Injection for EBV DNAemia After Allogeneic Hematopoietic Stem Cell Transplantation

Phase 1/2 Recruiting

Epstein-Barr Virus Infections

NCT07368153 2026-01-26

IDEP

Phase 2 Not yet recruiting

Epstein-Barr Virus Infections